


Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
first class mail in an envelope addressed to: Commissioner  
for Patents, PO Box 1450, Alexandria, VA 22313-1450 on  
this 30th day of June 2004

PC25581A  
IDS for For Appln. No. 10/816,242  
Page 1 of 1

IFW



*Julie Agozino*  
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
James FREDDO et al.

Group Art Unit: 1614

Serial No.: 10/816,242

Examiner: Not Yet Assigned

Confirmation No.: 9207

Filed: April 1, 2004

For: DOSAGE FORMS AND METHODS  
OF TREATMENT USING VEGFR INHIBITORS

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

- ☐ Applicant requests that the Examiner consider the following copending applications:


Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. . Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☒ This application was filed after June 30, 2003, or entered U.S. national stage under 35 U.S.C. § 371, after June 30, 2003. Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (1276 OG 55).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 500329. A duplicate copy of this form is enclosed.

Respectfully submitted,

Date: June 30, 2004


  
\_\_\_\_\_  
Stephen D. Prodnuk  
Attorney For Applicant  
Registration No. 43,020

Agouron Pharmaceuticals, Inc.  
A Pfizer Company  
Legal Division, Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233

Certificate of Mailing (37 C.F.R. § 1.8);  
I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
first class mail in an envelope addressed to: Commissioner  
for Patents, PO Box 1450, Alexandria, VA 22313-1450 on  
this 30th day of June 2004

PC25581A  
IDS for For Appl. No. 10/816,242  
Page 1 of 1

IFW



Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
James FREDDO et al.

Group Art Unit: 1614

Serial No.: 10/816,242

Examiner: Not Yet Assigned

Confirmation No.: 9207

Filed: April 1, 2004

For: DOSAGE FORMS AND METHODS  
OF TREATMENT USING VEGFR INHIBITORS

Honorable Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.97(b)**

**37 CFR § 1.97(b)**

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

**37 CFR § 1.97(c)**

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 500329.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	5,587,458	12/24/1996	King et al.	
	AB	5,747,498	05/05/1998	Schnur et al.	
	AC	5,792,783	08/11/1998	Tang et al.	
	AD	5,834,504	11/10/1998	Tang et al.	
	AE	5,861,510	01/19/1999	Piscopio et al.	
	AF	5,863,949	01/26/1999	Robinson et al.	
	AG	5,877,305	03/02/1999	Huston et al.	
	AH	5,883,113	03/16/1999	Tang et al.	
	AI	5,886,020	03/23/1999	Tang et al.	
	AJ	6,531,491	03/11/2003	Kania et al.	
	AK	6,534,524	03/18/2003	Kania et al.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AL	EP606,046	12/21/1993	Novartis AG		
	AM	EP780,386	12/10/1996	F. Hoffmann-La Roche AG		
	AN	EP931,788	12/16/1998	Pfizer Limited		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

JUL 02 2004

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

AO	WO90/05719	05/31/1990	British Bio-Technology Limited		
AP	WO95/19970	07/27/1995	Warner-Lambert Company		
AQ	WO95/21613	08/17/1995	Sugen, Inc.		
AR	WO96/14843	05/23/1996	Cor Therapeutics, Inc.		
AS	WO96/27583	09/12/1996	Pfizer Inc.		
AT	WO96/33172	10/24/1996	Pfizer Inc.		
AU	WO97/13760	04/17/1997	Glaxo Group Limited		
AV	WO97/22596	06/26/1997	Zeneca Limited		
AW	WO98/02434	01/22/1998	Glaxo Group Limited		
AX	WO98/02437	01/22/1998	Glaxo Group Limited		
AY	WO98/02438	01/22/1998	Glaxo Group Limited		
AZ	WO98/03516	01/29/1998	Pfizer Inc.		
BA	WO98/07697	02/26/1998	Pfizer Inc.		
BB	WO98/14451	04/09/1998	Novartis AG		
BC	WO98/30566	07/16/1998	Pfizer Inc.		
BD	WO98/33768	08/06/1998	Pfizer Products Inc.		
BE	WO98/34915	08/13/1998	Pfizer Inc.		
BF	WO98/34918	08/13/1998	Pfizer Inc.		
BG	WO98/50356	11/12/1998	Sugen, Inc.		
BH	WO98/54093	12/03/1998	Merck & Co., Inc.		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

BI	WO99/10349	03/04/1999	Zeneca Limited		
BJ	WO99/16755	04/08/1999	Merck & Co., Inc.		
BK	WO99/24440	05/20/1999	Pfizer Products Inc.		
BL	WO99/29667	06/17/1999	Pfizer Inc.		
BM	WO99/35132	07/15/1999	Glaxo Group Limited		
BN	WO99/35146	07/15/1999	Glaxo Group Limited		
BO	WO99/52889	10/21/1999	Pfizer Products Inc.		
BP	WO99/52910	10/21/1999	Pfizer Products Inc.		
BQ	WO99/61422	12/02/1999	Sugen, Inc.		
BR	WO00/37107	06/29/2000	G.D. Searle & Co.		
BS	WO00/38665	07/06/2000	G.D. Searle & Co.		
BT	WO00/38715	07/06/2000	G.D. Searle & Co.		
BU	WO00/38716 A1	07/06/2000	G.D. Searle & Co.	Corrected Version	
BV	WO00/38717	07/06/2000	G.D. Searle & Co.		
BW	WO00/38718	07/06/2000	G.D. Searle & Co.		
BX	WO00/38719	07/06/2000	G.D. Searle & Co.		
BY	WO00/38730	07/06/2000	G.D. Searle & Co.		
BZ	WO00/38786	07/06/2000	G.D. Searle & Co.		

## NON PATENT LITERATURE DOCUMENTS

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/816,242
Filing Date	April 1, 2004
First Named Inventor	James Freddo et al.
Art Unit	1614
Examiner Name	TBD
Attorney Docket Number	PC25581A

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	JEFFREY, Phillip D. et al., "Mechanism of CDK Activation Revealed by the Structure of a CyclinA-CDK2 Complex," <i>Nature</i> , 1995, 376, 313-320.	
	CB	MOHAMMADI, M. et al., "Identification of Six Novel Autophosphorylation Sites on Fibroblast Growth Factor.....Transduction," 1996, 16:3, 977-989.	
	CC	PARAST, C. et al, "Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular....Angiogenesis," <i>Biochemistry</i> , 1998, 37, 16788-16801.	
	CD	ROSENBLATT, Jody et al., "Purification and Crystallization of Human Cyclin-dependent Kinase 2," <i>Journal of Molecular Biology</i> , 1993, 230, 1317-1319.	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.